[Clinical Study of Ibrutinib Combined with Venetoclax Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma].
Ibrutinib combined with venetoclax can be used as an effective treatment regimen for R/R DLBCL, and NCCN-IPI can be used as a prognostic indicator. Objective remission after chemotherapy is beneficial for R/R DLBCL patients to achieve better OS.
Authors
- Lu-Yao Zhu (ORCID: https://orcid.org/0000-0001-8341-2024)
- Ling-Xiu Zhang
- Yuan Zhang (ORCID: https://orcid.org/0000-0002-4174-0641)
- Xiufeng Wang (ORCID: https://orcid.org/0000-0002-9557-049X)
- Youmei Zi
- Yan Huang (ORCID: https://orcid.org/0000-0002-5588-0274)
- Man Yang
Institutions
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Xinxiang University (CN)
- Henan Medical University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2024-10-01
- DOI
- https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.05.017
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article